Functional Characterization of CD8+ T Cells After Supramaximal Exercise
NCT06484101 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2024-07-03
Summary
Healthy human subjects perform supramaximal exercise with venous blood samples obtained before and up to 60 minutes after the exercise bout.
Conditions
- Exercise Induced CD8+ T Cell Recruitment and Characterization of Function and Phenotype of These Cells
Interventions
- PROCEDURE
-
Exercise
3 x 30 seconds of supramaximal exercise
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Helene Rundqvist, PhD · Karolinska Institutet
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 36 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-03-31
- Primary Completion
- 2023-12-22
- Completion
- 2024-02-14
Countries
- Sweden
Study Locations
More Related Trials
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Immune Repertoire of Ovarian HGSC
NCT03794115 ·Status: UNKNOWN
-
Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)
NCT03747744 ·Status: UNKNOWN ·Phase: PHASE1
-
Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients
NCT05062525 ·Status: COMPLETED
-
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
NCT04362865 ·Status: COMPLETED
-
Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
NCT06131775 ·Status: RECRUITING ·Phase: NA
-
Prospective Study of White Blood Cells
NCT04838171 ·Status: RECRUITING
-
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
NCT04214717 ·Status: UNKNOWN ·Phase: NA
-
Study of the Anti-tumoral Immune Response
NCT02854644 ·Status: COMPLETED ·Phase: NA
-
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
NCT00085930 ·Status: COMPLETED ·Phase: PHASE1
-
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
NCT05230186 ·Status: UNKNOWN
-
Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer
NCT07131566 ·Status: RECRUITING
-
T Cell Response in Hypersensitivity Syndrome
NCT00213447 ·Status: COMPLETED
-
Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer
NCT03113019 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Tumor-specific T Cells in Lung Cancer
NCT02515760 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Host Immune Response to Novel RNA COVID-19 Vaccination
NCT04784689 ·Status: COMPLETED
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
NCT03207854 ·Status: RECRUITING
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT02479698 ·Status: RECRUITING ·Phase: PHASE2
-
Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults
NCT00346619 ·Status: COMPLETED ·Phase: PHASE1
-
Thymic Function in Patients With COVID-19
NCT04716907 ·Status: COMPLETED
-
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
NCT04742595 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
NCT01567891 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
NCT02562963 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2